Why are we doing this research?
This phase I trial studies the side effects and best dose of flotetuzumab and how well it works with cytarabine in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Immunotherapy with flotetuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving flotetuzumab and cytarabine may stop the cancer from growing or shrink for a period of time, as well as possibly lessening symptoms, such as pain, that are caused by the cancer.
PEPN1812 A PHASE 1 TRIAL OF THE CD123 X CD3 DUAL AFFINITY RE-TARGETING ANTIBODY FLOTETUZUMAB (NSC#808294, IND#145986) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA